WooGene B&G Co., Ltd (KOSDAQ:018620)

South Korea flag South Korea · Delayed Price · Currency is KRW
895.00
+5.00 (0.56%)
At close: Apr 23, 2025, 3:30 PM KST
-17.89%
Market Cap 25.97B
Revenue (ttm) 55.68B
Net Income (ttm) -5.22B
Shares Out 28.89M
EPS (ttm) -181.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 60,618
Average Volume 67,479
Open 880.00
Previous Close 890.00
Day's Range 879.00 - 900.00
52-Week Range 823.00 - 1,216.00
Beta 0.66
RSI 61.59
Earnings Date May 12, 2025

About WooGene B&G

WooGene B&G Co., Ltd. engages veterinary medicines, microbial technology, and vaccines business in South Korea and internationally. It offers antibiotic, vaccine, nutrient, anti-inflammation, metabolic stimulant, and iron supplement products for swine, poultry, cattle, aquatic animals, companion animals, and raw materials, as well as operates vaccine research center. The company was formerly known as WooJin Co., Ltd. and changed its name to WooGene B&G Co., Ltd. in March 2001. WooGene B&G Co., Ltd. was founded in 1977 and is headquartered in Hw... [Read more]

Industry Pharmaceutical Preparations
Founded 1977
Employees 84
Stock Exchange KOSDAQ
Ticker Symbol 018620
Full Company Profile

Financial Performance

In 2024, WooGene B&G's revenue was 55.68 billion, a decrease of -3.87% compared to the previous year's 57.92 billion. Losses were -5.22 billion, 341.0% more than in 2023.

Financial Statements

News

There is no news available yet.